Perfluorooctanoic acid (PFOA) is a fully fluorinated eight-carbon perfluoroalkyl acid (PFAA) with a carboxylic acid functional group. As with other PFAAs, PFOA is used in the production of fluorochemicals, which have extensive commercial applications ([@r13]). PFOA is also a final breakdown product of certain fluorochemicals and resists degradation in the ambient environment by biota or physical processes ([@r10]). The ubiquity of fluorochemicals in the marketplace, combined with the persistence of PFOA in the environment, may explain current widespread PFOA contamination of humans and wildlife ([@r5]; [@r6]; [@r11]).

The average nonoccupationally exposed American exhibits measurable serum PFOA, varying between a mean concentration of 3.9 ng/mL among participants in the 2003--2004 National Health and Nutrition Examination Survey ([@r2]) and 2.2 ng/mL in 2005 among a smaller group of Red Cross blood donors ([@r12]). Occupational exposure can raise serum concentrations more than 200 times this approximate range ([@r3]). In the Little Hocking district of Ohio and West Virginia where the municipal drinking-water supply was contaminated with PFOA at 3.55 ng/mL (ppb) by nearby production plants, mean human serum concentrations were 423 ng/mL ([@r3]). Thus, nonoccupationally exposed Americans may receive substantial unforeseen exposures to PFOA. It is not known, however, whether adverse adult health effects could result from these chronic, low-level exposures beginning in early life. This is of particular interest with respect to development, because the potential toxicity of PFOA in humans remains uncharacterized.

Mouse studies have demonstrated the capacity for gestational PFOA exposure to yield developmental toxicity ([@r7], [@r8]; [@r17]). The mammary gland, specifically, has proven to be a sensitive tissue with respect to the developmental end points addressed, including functional lactation, milk protein gene expression, and developing neonatal and peripubertal structures ([@r15], [@r16]; [@r18]; [@r19]). In outbred CD-1 mice, treatment with 3 mg/kg PFOA during pregnancy resulted in delayed gland development among offspring, which persisted into adulthood, even among offspring with lactational exposures only ([@r16]). Another laboratory examined similar dose ranges using peripubertal exposures \[postnatal days (PNDs) 21--50\] in two inbred mouse strains, C57Bl/6 and Balb/C. The researchers observed a similar inhibitory effect on mammary gland development in Balb/C mice ([@r18]), whereas C57Bl/6 females exhibited stimulatory or inhibitory effects depending on dose ([@r18]; [@r19]). These observations illustrate the influence not only of dose but also of exposure timing and genetic background. They confirm that the mammary gland represents a sensitive tissue in multiple mouse strains.

To understand the extended consequences of altered mammary gland development, we performed a multigenerational study examining the ability of the developmentally exposed females to provide lactational support for their litters. To address the human relevance of the route, dose, and duration of exposures employed in our studies, we included a chronic low-dose exposure.

Materials and Methods
=====================

*Animals.* Timed-pregnant CD-1 mice were purchased from Charles River Laboratories (Raleigh, NC). Sperm-positive females \[gestational day (GD) 0\] were weighed upon arrival at the U.S. Environmental Protecion Agency (EPA). Animals were housed individually in polypropylene cages, and received food (LabDiet 5001; PMI Nutrition International LLC, Brentwood, MO) and tap water *ad libitum* in polyethylene water bottles sealed with rubber stoppers and stainless-steel sipper tubes, as specified by [@r16]. Animal protocols were approved by the U.S. EPA's Institutional Animal Care and Use Committee. Animals were treated humanely and with regard for alleviation of suffering.

*Dosing solutions.* PFOA (ammonium perfluorooctanoate; \> 98% pure) was purchased from Fluka Chemical (Steinheim, Switzerland). PFOA was dissolved by agitation in deionized water at concentrations of 0.1 and 0.5 mg/mL (for 1 and 5 mg/kg doses, respectively) and prepared fresh daily, immediately before administration. PFOA-containing drinking water was prepared similarly, by serial dilution to a final concentration of 5 ng/mL (ppb). Drinking water was prepared fresh weekly, and cage bottles were refilled weekly after rinsing.

*Study design.* A study timeline is shown in Supplemental Material, [Figure 1](#f1){ref-type="fig"} (doi:10.1289/ehp.1002741). Timed pregnant P~0~ (parental generation) dams were randomly distributed among five treatment groups. Three groups were treated once daily by oral gavage on GDs 1--17 (designated "gestational") with PFOA doses of 0 (control; *n* = 10), 1 (*n* = 12), or 5 mg/kg body weight (*n* = 11). The remaining two groups received PFOA at 0 (*n* = 7) or 1 mg/kg (*n* = 10) as described above, but also received PFOA (5 ppb) in their drinking water (designated "chronic") to approximate the 3.55 ppb PFOA present in the contaminated drinking- water supply in Little Hocking, Ohio ([@r3]). These two groups received PFOA-containing drinking water throughout gestation (starting on GD7) and for the duration of the study, as did subsequent F~1~ and F~2~ offspring (except during F~1~ breeding and early gestation, to avoid exposing control males). Weekly water consumption was calculated per cage by weighing bottles when filled and again at the end of the week; the differential reflected consumption.

![F~1~ female mammary gland development. Mammary whole-mounts illustrate morphology representative of treatment groups at PNDs 22, 42, and 63 (*n* = 6--7 females/treatment/age). Bars = 1,000 μm for PND22 and 2,000 μm for PND42 and PND63.](ehp.1002741.g001){#f1}

P~0~ dams were weighed daily throughout gestation. On PND1, F~1~ litters were weighed and sexed. F~1~ neonates were pooled and randomly redistributed to dams of their respective treatment groups, consistent with previous studies ([@r8]; [@r16]), equalizing litters to 12--13 neonates, with similar sex representation. Litters were monitored and weighed on PND10. On PND22, F~1~ offspring were weaned, and dams and 1--2 female offspring/litter were weighed and necropsied (*n* = 5--7 litters/treatment  group). A subset of F~1~ females were maintained into adulthood and weighed and necropsied at PND42 and PND63 (*n* = 6--8/treatment group).

Remaining adult F~1~ females were bred to age-matched control F~1~ males at 7--8 weeks of age, on the night of proestrus (determined by vaginal cytology). Breeding pairs remained together overnight only, and plug-positive females (GD0) were housed individually and monitored over gestation (*n* = 7--10 F~1~ dams/treatment group). On PND1, F~2~ neonates were weighed and sexed. F~2~ litters were equalized to 10 neonates for the lactational challenge experiment. F~1~ dams and 3 female offspring per F~2~ litter were sacrificed on either PND10 or PND22. The remaining F~2~ females were weaned and necropsied on either PND42 or PND63 (*n* = 4--8/treatment group).

The lactational challenge experiment was performed with F~1~ dams and their F~2~ litters on PND10, the peak of lactation. Dams were separated from offspring for 3 hr and then returned to their litters and allowed to nurse for 30 min. The time between reunion and initiation to nurse (arched back position over the litter) was recorded to the nearest second, as was the weight of the 10-pup litter before and after precisely 30 min of nursing, in order to estimate the volume of milk produced during the nursing period. Dams were euthanized and necropsied immediately after nursing.

*Necropsy.* All animals were terminated by decapitation; trunk blood was collected and serum was isolated and stored at --80°C in snap-top polypropylene tubes for PFOA analysis. Uteri were dissected from P~0~ and F~1~ dams, and implantation sites were visually identified by light macroscope (Leica WILD M420 macroscope; Leica, Wetzlar, Germany) to assess postimplantation loss per dam. Mammary glands were collected as described below.

*Mammary gland preparation.* Mammary glands were removed from P~0~ and F~1~ dams on PND10 (F~1~ dams only) and PND22 (*n* = 4--12/treatment group) because these times represent peak lactational output and weaning, respectively. In F~1~ and F~2~ offspring, a set of fourth and ﬁfth glands was removed from the skin and ﬂattened onto glass slides. Whole-mounts were ﬁxed in Carnoy's solution, stained in carmine alum, and then dehydrated and cleared in xylene, as previously described ([@r4]). From dams only, a portion of the contralateral mammary gland was removed, placed in a histology cassette, ﬁxed in 10% neutral buffered formalin for 48 hr, and stored in 70% ethanol. These tissues were embedded in parafﬁn, and 5 μm sections were prepared and stained with hematoxylin and eosin (H&E). Whole-mounts and histological sections were visualized by light macroscope.

Mammary gland whole-mounts from F~1~ and F~2~ female offspring were scored on a 1--4 subjective, age-appropriate developmental scale (4 = excellent development/structure; 1 = poor development/structure). The number of primary ducts and large secondary ducts, lateral side branching, appearance of budding from the ductal tree, and longitudinal outgrowth of the epithelia were assessed. Because we did not address estrous cycle stage at the time of necropsy, we did not include stage-sensitive morphological traits in scoring criteria. Slides were separated by score during evaluation, compared within a score for consistency, and then recorded. Two individuals, blind to treatment, scored glands. Mean scores for the various ages and treatment groups were calculated and analyzed statistically for treatment and time-related differences.

H&E-stained lactating mammary gland sections from P~0~ and F~1~ dams were similarly scored on a 1--4 subjective scale. A value of 4 represented well-differentiated, functionally lactating tissue characterized by extensive epithelium, reduced adiposity, and presence of secretory alveoli, consistent with the peak of lactation (PND10, as previously described by [@r14]). A value of 1 represented little or diminishing presence of lobuloalveoli and extensive involution and regression of the tissue, with the presence of apoptotic bodies, increasing adiposity, and regressing alveoli, as anticipated at weaning (PND22). At both time points, dams were euthanized immediately after removal from litters to ensure comparable lactational morphology. Mammary glands representing the mean score or observation for each treatment group were photographed using the described macroscope and mounted camera (Photometrics CoolSNAP; Roper Scientiﬁc, Inc., Tucson, AZ).

*Measurement of PFOA in serum.* Serum samples from the P~0~ and F~1~ dams at PND22 and from F~1~ and F~2~ offspring at PNDs 22, 42, and 63 were stored frozen in snap-top polypropylene vials until they were shipped on dry ice to the Centers for Disease Control and Prevention (CDC) laboratory. Serum PFOA measurements were performed by the CDC using the methodology described in detail by [@r16].

*Data analysis.* Data were evaluated for dose effects using mixed-model analysis of variance in SAS (version 9.1; SAS Institute Inc., Cary, NC). For both generations, treatment-specific mean gestational weight gain was calculated for dams between GD1 and GD17, and treatment-specific mean body weights were determined for F~1~ and F~2~ offspring on PNDs 22, 42, and 63. In addition, we calculated F~2~ offspring body weight means at PNDs 1, 3, 5, 10, 14, and 17, based on whole-litter weights (divided by number of pups; litter used as the unit of measure before weaning). For all three generations, mean mammary gland lactational or developmental scores were calculated. Scores were analyzed using body weight at time of collection as a random effect, with litter as the unit of measure for neonatal scores. For both P~0~ and F~1~ dams, we calculated mean implant number, percentage of postimplantation (prenatal) loss, and percentage of postnatal survival. Differences between treatment groups were determined using Dunnett's, Tukey's, or Student's *t*-tests, with significance set at *p* \< 0.05 for all comparisons.

Results
=======

*P~0~ dams and F~1~ offspring.* We found no significant effect of PFOA on P~0~ dam gestational weight gain or implant number ([Table 1](#t1){ref-type="table"}). Consistent with previous studies ([@r15], [@r16]; [@r17]), gestational 5 mg/kg PFOA significantly reduced the number of live fetuses, prenatal survival, and postnatal offspring growth and survival, but similar effects were not observed with 1 mg/kg PFOA or with drinking-water treatment ([Table 1](#t1){ref-type="table"}). Given these observations in P~0~ dams---and in agreement with the conclusions of prior studies ([@r8]; [@r17])---maternal toxicity was not responsible for F~1~ developmental deficits seen at low exposures.

###### 

P~0~ maternal indices (mean ± SE; *n* = 7--11).

  Maternal index                            Control   Control + 5 ppb PFOA   1 mg/kg   1 mg/kg + 5 ppb PFOA   5 mg/kg                                     
  ----------------------------------------- --------- ---------------------- --------- ---------------------- --------- ------------- -- ------------- -- --------------
  Gestational weight gain (g)                         24.8 ± 1.2                       25.0 ± 1.2                       26.0 ± 1.2       27.0 ± 1.2       27.7 ± 1.2
  Implants (no. per live litter)                      12.8 ± 0.5                       12.7 ± 0.4                       13.5 ± 0.7       14.0 ± 0.4       13.7 ± 0.6
  Live fetuses (no. per live litter)                  12.0 ± 0.5                       11.7 ± 0.4                       12.9 ± 0.7       13.3 ± 0.5       10.0 ± 0.8\*
  Prenatal loss (% per live litter)                   6.1 ± 1.8                        7.8 ± 1.7                        4.5 ± 1.7        5.1 ± 1.6        25.8 ± 5.6\*
  Postnatal survival (% per live litter)              96.1 ± 1.3                       100 ± 0.0\*                      98.8 ± 0.8       89.5 ± 6.4       72.7 ± 5.8\*
  Mammary gland score (1--4 scale), PND22             2.4 ± 0.2                        3.4 ± 0.1\*                      3.0 ± 0.2\*      3.2 ± 0.2\*      3.9 ± 0.1\*
  \**p* \< 0.05 compared with control.                                                                                                                    

As evidenced by significantly elevated histological scores at PND22, normal weaning-induced mammary involution was compromised among all PFOA-treated P~0~ dams, including those with only low-dose exposures via drinking water ([Table 1](#t1){ref-type="table"}). In contrast with the extensive gland regression observed in control dams at weaning, glands in PFOA-treated dams at PND22 demonstrated structural similarity to normal dam mammary tissue at or near the peak of lactation at PND10, including the presence of functional lobuloalveolar units (data not shown). This observation was consistent with our previous finding that gestational PFOA exposure delays lactational differentiation and eventual involution in the exposed dam ([@r15]), but here we also observed the effect with exposure to 5 ppb PFOA in drinking water for a total of 34 days \[for dose estimates, see Supplemental Material, [Table 1](#t1){ref-type="table"} (doi:10.1289/ehp.1002741)\].

F~1~ offspring body weights and adjusted body weights (body weight less liver weight) between PND22 and PND63 were not consistently associated with PFOA treatment ([Table 2](#t2){ref-type="table"}). Liver:body weight ratios at PND22 were significantly elevated among F~1~ females exposed to 1 or 5 mg/kg, consistent with hepatomegaly. At PND42, F~1~ females exposed to 5 mg/kg had significantly increased liver:body weight ratios and significant reductions in total and adjusted body weight, but all three parameters were similar to controls by 9 weeks of age (PND63). Chronic 5 ppb PFOA exposure in drinking water did not affect the liver:body weight ratio in F~1~ offspring. In contrast, developmental mammary scores of F~1~ offspring were significantly reduced among all treatment groups (including 5 ppb in water) until at least 9 weeks of age (PND63; [Table 2](#t2){ref-type="table"}, [Figure 1](#f1){ref-type="fig"}), suggesting that delayed mammary gland development is a more sensitive and persistent end point than is hepatomegaly.

###### 

F~1~ developmental indices (mean ± SE; *n* = 4--10).

  Developmental index                                                           Control   Control + 5 ppb PFOA   1 mg/kg   1 mg/kg + 5 ppb PFOA   5 mg/kg                                            
  ----------------------------------------------------------------------------- --------- ---------------------- --------- ---------------------- --------- --------------- -- ------------------ -- ----------------
  Body weight (g)                                                                                                                                                                                    
  PND22                                                                                   12.70 ± 0.69                     12.69 ± 0.87                     13.40 ± 0.49       13.20 ± 0.37          11.28 ± 0.45
  PND42                                                                                   25.65 ± 0.43                     24.28 ± 0.57                     24.24 ± 0.74       24.90 ± 0.62          22.28 ± 0.60\*
  PND63                                                                                   28.77 ± 0.96                     26.23 ± 1.81                     29.93 ± 0.97       26.35 ± 0.84^\#^      27.88 ± 1.25
  Liver:body weight ratio (×100%)                                                                                                                                                                    
  PND22                                                                                   5.56 ± 0.16                      5.29 ± 0.13                      6.35 ± 0.08\*      5.96 ± 0.12           7.81 ± 0.34\*
  PND42                                                                                   5.19 ± 0.24                      5.75 ± 0.22                      5.32 ± 0.10        5.26 ± 0.13           5.79 ± 0.09\*
  PND63                                                                                   4.85 ± 0.17                      4.99 ± 0.12                      4.97 ± 0.13        4.82 ± 0.15           5.24 ± 0.28
  Body weight excluding liver weight (g)                                                                                                                                                             
  PND22                                                                                   11.99 ± 0.64                     11.16 ± 0.86                     12.55 ± 0.46       12.55 ± 0.36          10.39 ± 0.39
  PND42                                                                                   24.32 ± 0.44                     22.89 ± 0.54                     22.94 ± 0.69       23.59 ± 0.58          20.99 ± 0.57\*
  PND63                                                                                   27.38 ± 0.94                     24.92 ± 1.74                     28.49 ± 1.12       24.43 ± 1.09          26.43 ± 1.24
  Mammary gland score (1--4 scale)                                                                                                                                                                   
  PND22                                                                                   3.8 ± 0.1                        2.5 ± 0.2\*                      2.3 ± 0.2\*        2.2 ± 0.1\*           1.6 ± 0.1\*
  PND42                                                                                   3.8 ± 0.1                        3.3 ± 0.2\*                      2.6 ± 0.4\*        2.2 ± 0.3\*           2.3 ± 0.2\*
  PND63                                                                                   3.8 ± 0.2                        2.6 ± 0.4\*                      2.9 ± 0.2\*        2.0 ± 0.3\*^\#^       2.2 ± 0.2\*
  \**p* \< 0.05 compared with control. ^\#^*p* \< 0.05 compared with 1 mg/kg.                                                                                                                        

*F~1~ dams and F~2~ offspring.* We did not observe maternal toxicity in F~1~ dams with developmental or chronic low-level PFOA exposures. Interestingly, the number of uterine implants was significantly reduced among F~1~ dams developmentally exposed to 5 mg/kg, resulting in litters with significantly fewer offspring ([Table 3](#t3){ref-type="table"}). As previously described, postnatal survival of 5 mg/kg F~1~ females was significantly decreased; however, we observed no effect on this end point with respect to postnatal survival of F~2~ offspring. This suggests that both F~2~ thriftiness---specifically referring to the ability to suckle with sufficient vigor and frequency, so as to yield nourishment---and F~1~ lactational competency were sufficient to support litters.

###### 

F~1~ maternal indices (mean ± SE; *n* = 4--10).

  Maternal index                           Control   Control + 5 ppb PFOA   1 mg/kg   1 mg/kg + 5 ppb PFOA   5 mg/kg                                     
  ---------------------------------------- --------- ---------------------- --------- ---------------------- --------- ------------- -- ------------- -- --------------
  Implants (no. per live litter)                     14.9 ± 0.4                       14.6 ± 0.5                       14.1 ± 0.4       13.4 ± 0.9       12.3 ± 0.2\*
  Live fetuses (no. per live litter)                 13.6 ± 0.6                       13.1 ± 0.6                       12.8 ± 0.6       12.1 ± 0.9       12.0 ± 0.3\*
  Prenatal loss (% per live litter)                  8.6 ± 2.5                        9.8 ± 3.2                        10.0 ± 3.2       6.7 ± 2.5        2.7 ± 1.4
  Postnatal survival (% per live litter)             100 ± 0.0                        100 ± 0.0                        98.1 ± 1.4       97.9 ± 1.5       100 ± 0.0
  Lactational challenge                                                                                                                                  
  Milk produced in 30 min (g)                        2.10 ± 0.20                      1.80 ± 0.35                      2.08 ± 0.25      1.40 ± 0.44      1.73 ± 0.51
  Time to initiate (sec)                             267 ± 38                         384 ± 55                         307 ± 114        351 ± 86         279 ± 30
  Mammary gland score (1--4 scale)                                                                                                                       
  PND10                                              4.0 ± 0.0                        2.8 ± 0.5\*                      2.5 ± 0.2\*      2.0 ± 0.2\*      2.5 ± 0.2\*
  PND22                                              2.1 ± 0.3                        2.2 ± 0.2                        1.9 ± 0.4        1.5 ± 0.2\*      3.2 ± 0.3\*
  \**p* \< 0.05 compared with control.                                                                                                                   

In the lactational challenge on PND10, neither milk volume nor timed nursing behavior was significantly different from controls with gestational (P~0~) or chronic, low-level PFOA exposure of the F~1~ dams ([Table 3](#t3){ref-type="table"}). Although we noted large differences in mean values (i.e., one-third reduction in milk transferred to offspring as measured by litter weight and an 84-sec longer time to suckling in the 1-mg/kg + 5 ppb PFOA exposure group compared with controls), high variability in these responses limited the power to detect a significant difference. Nevertheless, F~1~ lactational morphology was significantly compromised among all treatment groups at PND10 ([Table 3](#t3){ref-type="table"}, [Figure 2](#f2){ref-type="fig"}). By PND22, most morphological delays were no longer evident, and only F~1~ dams with the highest developmental exposure (i.e., 5 mg/kg PFOA) still exhibited morphology that was significantly different from controls, with little evidence of normal regression. Consistent with this, we observed productive spherical alveoli in the 5 mg/kg group, in contrast with the regressing alveoli and apoptotic bodies observed in controls. Of note, at the time F~1~ dams became pregnant and underwent lactational differentiation, their virgin siblings still exhibited stunted mammary gland development in all exposure groups compared with controls (PND63; [Table 2](#t2){ref-type="table"}, [Figure 1](#f1){ref-type="fig"}).

![Histological sections of lactating mammary glands from F~1~ dams. Glands pictured illustrate morphology representative of respective treatments at given times (*n* = 4 dams/treatment/time point). Arrows indicate presence of alveoli. Bars = 100 μm.](ehp.1002741.g002){#f2}

Despite striking morphological abnormalities in the lactating glands of PFOA-exposed F~1~ dams on PND10, we found no clear evidence of diminished nutritional support provided by these dams based on F~2~ body weights ([Table 4](#t4){ref-type="table"}). These data suggest that nursing behavior of the neonates may have changed (i.e., increased number of nursing events per day or longer nursing per event) to compensate for the decreased potential in milk production by the F~1~ dam, but we did not evaluate these end points in this study. Adjusted body weights and liver:body weight ratios did not demonstrate clear differences by treatment group in the F~2~ offspring ([Table 4](#t4){ref-type="table"}).

###### 

F~2~ developmental indices (mean ± SE; *n* = 4--10).

  Developmental index                                                           Control   Control + 5 ppb PFOA   1 mg/kg   1 mg/kg + 5 ppb PFOA   5 mg/kg                                            
  ----------------------------------------------------------------------------- --------- ---------------------- --------- ---------------------- --------- ---------------- -- ----------------- -- --------------
  Body weight (g)                                                                                                                                                                                    
  PND1                                                                                    1.71 ± 0.03                      1.61 ± 0.03\*                    1.63 ± 0.05         1.68 ± 0.05          1.65 ± 0.04
  PND3                                                                                    2.27 ± 0.05                      2.22 ± 0.05                      2.25 ± 0.09         2.30 ± 0.09          2.22 ± 0.06
  PND5                                                                                    3.24 ± 0.07                      3.35 ± 0.10                      3.38 ± 0.11         3.42 ± 0.15          3.34 ± 0.09
  PND10                                                                                   5.69 ± 0.22                      5.83 ± 0.23                      6.00 ± 0.19         5.96 ± 0.18          5.87 ± 0.20
  PND14                                                                                   6.26 ± 0.06                      6.34 ± 0.05                      7.30 ± 0.25\*       7.54 ± 0.33          6.85 ± 0.26
  PND17                                                                                   6.64 ± 0.13                      7.05 ± 0.06                      8.15 ± 0.31\*       8.19 ± 0.39          7.42 ± 0.37
  PND22                                                                                   10.80 ± 0.28                     11.41 ± 0.26                     13.00 ± 0.50\*      13.29 ± 0.61         11.60 ± 0.54
  Liver:body weight ratio (×100%)                                                                                                                                                                    
  PND10                                                                                   2.94 ± 0.15                      2.94 ± 0.12                      3.08 ± 0.14         2.73 ± 0.14          2.91 ± 0.09
  PND22                                                                                   5.43 ± 0.14                      5.25 ± 0.25                      5.10 ± 0.21         5.18 ± 0.23          5.11 ± 0.15
  PND42                                                                                   5.43 ± 0.13                      5.47 ± 0.10                      5.78 ± 0.12         5.36 ± 0.19          5.63 ± 0.21
  PND63                                                                                   5.28 ± 0.25                      5.13 ± 0.19                      5.05 ± 0.11         5.10 ± 0.15          4.79 ± 0.25
  Body weight excluding liver weight (g)                                                                                                                                                             
  PND10                                                                                   6.20 ± 0.18                      6.15 ± 0.20                      6.16 ± 0.14         5.72 ± 0.29          6.44 ± 0.36
  PND22                                                                                   9.75 ± 0.58                      10.10 ± 0.18                     10.58 ± 0.54        11.29 ± 0.73         10.41 ± 0.78
  PND42                                                                                   22.28 ± 0.79                     24.07 ± 0.32                     24.12 ± 0.68        25.78 ± 0.55\*       24.12 ± 0.51
  PND63                                                                                   27.41 ± 0.76                     27.59 ± 1.22                     25.98 ± 1.29        28.83 ± 0.90         29.66 ± 2.10
  Mammary gland score (1--4 scale)                                                                                                                                                                   
  PND10                                                                                   2.8 ± 0.3                        3.0 ± 0.2                        1.9 ± 0.3           2.6 ± 0.2            2.0 ± 0.2
  PND22                                                                                   3.1 ± 0.4                        1.9 ± 0.3                        2.3 ± 0.1           2.3 ± 0.2            2.0 ± 0.2
  PND42                                                                                   3.5 ± 0.2                        2.5 ± 0.4\*                      3.4 ± 0.2           2.4 ± 0.2\*^\#^      3.3 ± 0.4
  PND63                                                                                   3.4 ± 0.2                        3.5 ± 0.2                        2.4 ± 0.2\*         2.6 ± 0.5            2.6 ± 0.4
  \**p* \< 0.05 compared with control. ^\#^*p* \< 0.05 compared with 1 mg/kg.                                                                                                                        

Unlike F~1~ females, developmental mammary gland scores in F~2~ females did not differ in association with maternal exposure; however, control F~2~ females exhibited unusually low mammary gland scores at PND10 and PND22, which might have reduced the statistical ability to detect effects in other treatment groups at these time points ([Table 4](#t4){ref-type="table"}). At PND22, scores were consistent with developmental delays in all treatment groups relative to controls, but contrasts were not statistically significant. By PND42, both groups with chronic drinking-water exposures (control + 5 ppb PFOA, 1 mg/kg + 5 ppb PFOA) displayed significantly reduced gland development relative to controls ([Table 4](#t4){ref-type="table"}) that was characterized by an excess of terminal end buds (TEBs) ([Figure 3](#f3){ref-type="fig"}). Furthermore, mammary gland scores for the F~2~ offspring of gestationally exposed F~1~ females in the 5 mg/kg group were generally consistent with delayed differentiation ([Table 4](#t4){ref-type="table"}), with histological evidence of postponed lobule formation (arrows in [Figure 3](#f3){ref-type="fig"}). We frequently observed a more sparse appearance in F~2~ mammary tissue from these three groups (data not shown), resulting from delayed ductal outgrowth and persistence of TEBs in adults (arrows in [Figure 3](#f3){ref-type="fig"}).

![F~2~ female mammary gland development. Mammary whole-mounts illustrate morphology representative of respective treatment groups at PNDs 10, 22, 42, and 63 (*n* = 4--5 females/treatment/age). Arrows indicate remaining TEBs. Bars = 500 μm for PND10, 1,000 μm for PND22, and 2,000 μm for PND42 and PND63.](ehp.1002741.g003){#f3}

*Water consumption.* We calculated average daily PFOA intake for the two groups receiving chronic drinking-water exposures from measurements of weekly water consumption \[see Supplemental Material, [Figure 2](#f2){ref-type="fig"} (doi:10.1289/ehp.1002741)\]. We found no difference in water intake between groups (as a function of P~0~ treatment), and daily estimated PFOA intake for drinking-water groups ranged from approximately 50 to 100 ng, excepting anticipated changes in water intake depending on life stage (i.e., increased intake during lactation, lower intake in early life; see Supplemental Material, [Table 1](#t1){ref-type="table"} and Supplemental Material, [Figure 2](#f2){ref-type="fig"}).

*Serum PFOA analyses.* In F~1~ offspring at 9 weeks of age (PND63; [Table 5](#t5){ref-type="table"}), serum PFOA concentrations in the 5 mg/kg group were only an order of magnitude greater than the levels exhibited in the chronic drinking water + 5 ppb PFOA exposure-only group. When F~1~ dams (then 13 weeks of age) were weaning their litters (F~2~ at PND22; [Table 5](#t5){ref-type="table"}), serum PFOA concentrations in the F~2~ drinking-water exposure groups had surpassed those of the F~2~ offspring of F~1~ dams developmentally exposed to 1 and 5 mg/kg  PFOA during their gestation. The control + 5 ppb PFOA group was particularly interesting, because averaged over their lifetimes (PNDs 22, 42, and 63, and \~ PND91 for F~1~ dams, means averaged for each respective generation), the F~1~ and F~2~ generations exhibited nearly identical average serum PFOA concentrations, 59.5 and 50.8 ng/mL, respectively. Furthermore, because the final serum measurement taken on the F~1~ generation was at 13 weeks postnatally (\~ PND91), compared with only 9 weeks for the F~2~ generation, the lifetime average may have been skewed slightly higher for the F~1~ generation. Serum PFOA concentrations did not differ significantly at any time point between the two drinking-water treatment groups in the F~2~ generation.

###### 

Serum PFOA concentrations (ng/mL) over three generations (mean ± SE).

  Generation/age                 Control   Control + 5 ppb PFOA   1 mg/kg   1 mg/kg + 5 ppb PFOA   5 mg/kg                                           
  ------------------------------ --------- ---------------------- --------- ---------------------- --------- ---------------- -- ---------------- -- ------------------
  P~0~ dams at weaning (PND22)             4.0 ± 0.3                        74.8 ± 11.3                      6658.0 ± 650.5      4772.0 ± 282.4      26980.0 ± 1288.2
  F~1~ pups                                                                                                                                          
  PND22                                    0.6 ± 0.3                        21.3 ± 2.1                       2443.8 ± 256.4      2743.8 ± 129.4      10045 ± 1125.6
  PND42                                    1.4 ± 0.4                        48.9 ± 4.7                       609.5 ± 72.2        558.0 ± 55.8        1581.0 ± 245.1
  PND63                                    3.1 ± 0.2                        66.2 ± 4.1                       210.7 ± 21.9        187.0 ± 24.1        760.3 ± 188.3
  F~1~ dams at weaning (PND22)             2.0 ± 0.6                        86.9 ± 14.5                      9.3 ± 2.6           173.3 ± 36.4        18.7 ± 5.2
  F~2~ pups                                                                                                                                          
  PND22                                    0.4 ± 0.0                        26.6 ± 2.4                       4.6 ± 1.2           28.5 ± 3.7          7.8 ± 1.9
  PND42                                    0.7 ± 0.3                        57.4 ± 2.9                       0.4 ± 0.0           72.8 ± 5.8          0.4 ± 0.0
  PND63                                    1.1 ± 0.4                        68.5 ± 9.4                       1.1 ± 0.5           69.2 ± 4.3          1.2 ± 0.5

Discussion
==========

Our prior studies identified morphological delays in mammary gland development that resulted from gestational PFOA exposure ([@r15], [@r16]), but we did not previously determine whether such morphological effects persisted and were associated with functional consequences, nor did we evaluate the effects of low-level, chronic exposures, similar to nonoccupational exposures in humans. In the present study, we found evidence that the previously reported effects on F~1~ offspring mammary development---resulting from treatment of P~0~ dams with 1 or 5 mg/kg PFOA during pregnancy---did persist and that these histopathological diminishments in the developing gland translated to altered lactational morphology, when F~1~ females were bred and challenged to lactationally support F~2~ litters. However, these effects were not associated with an overt reduction in the nutritional support provided by the F~1~ dam, because F~2~ offspring demonstrated normal postnatal survival and weight gain. Among F~1~ females that received only chronic low-level 5 ppb PFOA exposure, we also observed comparable and significant diminishments in developmental morphology between PND22 and PND63, as well as in later, adult lactational morphology at the peak of lactation, suggesting a far greater sensitivity of the tissue than previously identified. F~2~ offspring of these F~1~ dams with only chronic low-dose exposures also displayed a trend toward delayed development and exhibited significantly stunted morphology at PND42.

The degree to which these persistent alterations in F~1~ mammary gland morphology are associated with functional consequences is difficult to determine because impaired weight gain in F~2~ offspring was the only relevant end point assessed. The morphological effects of PFOA exposure in F~1~ mammary glands did not translate to significant decreases in growth and survival of F~2~ litters, as opposed to the case with F~1~ offspring of P~0~ dams. Nonetheless, an increase in the thriftiness of offspring from the F~1~ to F~2~ generations or an increase in F~2~ nursing frequency could have masked effects on milk production in affected lactating F~1~ glands.

These data suggest that chronic developmental exposure to environmentally relevant levels of PFOA may not interfere with lactation per se, but may reduce the number and density of alveoli available to produce milk and increase latency to peak milk output, delaying offspring maturation as seen in our previous work ([@r15]). In the case of humans, where viable alternatives to breast milk are available, low-level functional effects on lactation that cause even a short delay in substantial milk output might result in formula feeding instead of breast-feeding, despite the established health benefits of breast-feeding. In mammalian wildlife species, critically reliant upon lactation to raise their offspring, responsiveness of the gland to PFOA might lead to delays in milk production, resulting in malnourishment or possibly starvation of offspring, in a manner similar to the effects of polychlorinated biphenyls on wild mink reproduction in the past ([@r1]).

Chronic, low-dose PFOA exposure in drinking water at human-relevant levels (5 ppb) delayed mammary gland development in F~1~ offspring. This exposure yielded serum PFOA levels that ranged between 50 and 100 ng/mL after approximately 6 weeks ([Table 5](#t5){ref-type="table"}; lifetime averages: F~1~ females, 59.5 ng/mL; F~2~ females, 50.8 ng/mL; data not shown). If these approximate serum concentration ranges represent those of an animal reaching a steady-state burden, it should be noted that they are approximately an order of magnitude lower than that seen in some chronically exposed human populations. For example, communities exposed to 3.55 ppb PFOA in municipal supply drinking water exhibited mean serum PFOA concentrations of 423 ng/mL ([@r3]), compared with the national average of 3.9 ng/mL ([@r2]). Although it is understood that the pharmacokinetics of PFOA in the mouse differ from those in the human---the half-life being approximately 17 days in the mouse and 3.8 years in the human ([@r2]; [@r9])---it remains disconcerting that the effective circulating dose sufficient to yield histopathological changes in the mouse mammary gland is approximately an order of magnitude lower than the mean serum concentration in certain human populations.

These low serum concentrations were associated with alterations in mouse mammary gland morphology in three generations, although we could not separate the effects of postgestational chronic exposure in each generation from gestational exposure in some instances, so the effects observed in these treatment groups were not necessarily transgenerationally transmitted. Because humans with exposures under similar conditions (contaminated drinking water) exhibit higher circulating serum concentrations of PFOA, by an order of magnitude---and approximately two orders of magnitude above the concentration of PFOA in their exposure source---the data presented here may actually underrepresent human-relevant exposure conditions with respect to internal circulating dose. However, it is not known whether effects of PFOA on the mouse mammary gland translate to effects in humans; research is ongoing to discern a mammary-specific mode of action for PFOA and to determine its relevance to human breast health.

Conclusion
==========

Our studies identified a gestational exposure lowest observable adverse effect level (LOAEL) of 1 mg/kg PFOA for altered lactational morphology in treated P~0~ dams and altered mammary gland development in their F~1~ offspring. Additionally, our use of a nontraditional treatment regimen using low-dose continual exposure has generated data that will allow others to calculate a lower chronic exposure LOAEL or benchmark dose.

Delays in mammary epithelial growth in F~1~ females developmentally exposed to PFOA reported in this study and others ([@r15], [@r16]) translated to histopathological changes in subsequent lactational morphology. However, this did not result in functional deficits in lactation when F~2~ offspring growth and survival were used as proxy measures of nutritional support. We observed sparse branching morphology and delayed differentiation in three generations of CD-1 mice, but the global scoring method did not indicate consistent differences from controls across F~2~ time points.

Although the chronic low-dose PFOA supplied in drinking water in these studies and similar concentrations reported in municipal drinking-water supplies near fluorochemical plants are not representative of drinking- water supplies in the United States in general, PFOA is not regularly monitored in drinking water, so national averages cannot be well estimated. It is concerning, however, that the chronic low dose employed here was sufficient to produce changes in the development of the mouse mammary gland; similar developmental changes are physiologically possible in girls but would likely not be realized until they enter puberty or attempt lactation. Therefore, if human exposures in distinct populations are approximating those provided in this study, concerns over human breast health and lactational competency are justified.

Supplemental Material
=====================

###### 

Click here for additional data file.
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